Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6279256 | 1.00 | TSHR (0.41) | TSHRPPARDKDM4EATMMAPT | |
| SCHEMBL15475612 | 1.00 | TSHR (0.41) | TSHRPPARDKDM4EATMMAPT | |
| SCHEMBL6153093 | 0.81 | TSHR (0.39) | TSHRPPARDMAPTMAPK1CYP2D6 | |
| SCHEMBL2079724 | 0.81 | NPSR1 (0.44) | TSHRPPARDKDM4EMAPTMAPK1 | |
| SCHEMBL9246311 | 0.81 | TSHR (0.39) | TSHRPPARDMAPTMAPK1CYP2D6 | |
| SCHEMBL711893 | 0.81 | NPSR1 (0.44) | TSHRPPARDKDM4EMAPTMAPK1 | |
| SCHEMBL15475608 | 0.81 | KDM4E (0.35) | KDM4EATMCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11172103 | 0.80 | KDM4E (0.39) | KDM4EATM | |
| SCHEMBL11172053 | 0.80 | KDM4E (0.39) | KDM4EATM | |
| SCHEMBL11172080 | 0.80 | KDM4E (0.39) | KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-18 | — | — | US | disclosed |
| WO-2004108678-A1 | (1,2,3,4-TETRAHYDROQUINOLIN-8-YL)-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-6734193-B1 | REDUCE SERUM GLUCOSE AND SERUM TRIGLYCERIDE LEVELS IN DIABETIC MAMMALS WITHOUT THE UNDESIRABLE PROPERTIES OF REDUCING SERUM THYROXINE LEVELS AND TRANSIENTLY RAISING TRIGLYCERIDE LEVELS | ALLERGAN, INC. | 2004-05-11 | — | — | US | disclosed |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | ALLERGAN SALES, INC. | 2003-07-31 | — | — | US | disclosed |
| EP-0591046-B1 | Chromene derivatives with a triene chain for use in the treatment of osteoporosis inflammatory diseases | ADIR (FR) | 1998-12-02 | — | — | EP | disclosed |
| US-5700836-A | TOPICALLY ADMINISTERING TO TREAT PHOTODAMAGED SKIN | HOFFMANN-LA ROCHE INC. (US) | 1997-12-23 | — | — | US | disclosed |
| US-5391569-A | Treating osteoporosis, inflammatory disorders | ADIR ET COMPAGNIE (FR) | 1995-02-21 | — | — | US | disclosed |
| EP-0591046-A1 | Chromene derivatives with a triene chain for use in the treatment of osteoporosis inflammatory diseases | ADIR ET COMPAGNIE (FR) | 1994-04-06 | — | — | EP | disclosed |
| US-4975454-A | Triene compounds having a chromene structure | ADIR ET COMPAGNIE (FR) | 1990-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | TSHR 53/4885PPARD 44/4885KDM4E 4137/4885 |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | TSHR 311/4885PPARD 304/4885KDM4E 4666/4885 |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | RXRG, RXRB, RXRA | TSHR 53/4885PPARD 44/4885KDM4E 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.